Tenofovir ( DrugBank: Tenofovir )
6 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 25 | 進行性多巣性白質脳症 | 1 |
| 93 | 原発性胆汁性胆管炎 | 1 |
| 265 | 脂肪萎縮症 | 5 |
| 325 | 遺伝性自己炎症疾患 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02437110 (ClinicalTrials.gov) | April 1, 2019 | 5/5/2015 | HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Darunavir;Drug: Ritonavir;Drug: Dolutegravir;Drug: Tenofovir alafenamide (TAF) | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 200 | Phase 1 | United States |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04880577 (ClinicalTrials.gov) | September 15, 2022 | 30/4/2021 | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Fatigue | Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo | Harvard Medical School | Gilead Sciences | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | NULL |
25. 進行性多巣性白質脳症
臨床試験数 : 25 / 薬物数 : 35 - (DrugBank : 21) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00120367 (ClinicalTrials.gov) | April 2005 | 11/7/2005 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial | Leukoencephalopathy, Progressive Multifocal;HIV Infections | Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche;Gilead Sciences | Completed | 18 Years | N/A | Both | 30 | Phase 2 | France |
93. 原発性胆汁性胆管炎
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03954327 (ClinicalTrials.gov) | June 29, 2020 | 7/5/2019 | Combination Antiretroviral Therapy (cART) for PBC | Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA) | Primary Biliary Cholangitis | Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF);Drug: Raltegravir;Drug: Placebo Oral Capsule [CEBOCAP] | University of Alberta | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Canada |
265. 脂肪萎縮症
臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04903847 (ClinicalTrials.gov) | February 2, 2021 | 9/10/2020 | Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil | Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 | Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;Obesity | Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | Thomas Benfield | NULL | Recruiting | 18 Years | N/A | All | 126 | Phase 4 | Denmark |
| 2 | EUCTR2005-004021-26-GB (EUCTR) | 06/10/2005 | 05/09/2005 | Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study | Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study | HIV | Trade Name: SUSTIVA Product Name: Efavirenz Trade Name: COMBIVIR Product Name: AZT/3TC Trade Name: TRUVADA Product Name: emtricitabine/tenofovir | University Hospital Birmingham | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): yes | United Kingdom | ||
| 3 | NCT00119379 (ClinicalTrials.gov) | April 2005 | 11/7/2005 | Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults | Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy | HIV Infections;Lipodystrophy;Metabolic Diseases;Nutrition Disorders | Drug: NucleomaxX;Drug: Tenofovir Disoproxil Fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | N/A | All | 50 | Phase 2 | United States |
| 4 | NCT00647946 (ClinicalTrials.gov) | February 2003 | 27/3/2008 | Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue | A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART) | Lipodystrophy | Drug: tenofovir DF;Drug: abacavir 300mg twice daily | Gilead Sciences | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 2 | United Kingdom |
| 5 | NCT00192660 (ClinicalTrials.gov) | February 2003 | 12/9/2005 | HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) | Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time | HIV-Associated Lipodystrophy Syndrome;Cardiovascular Disease | Drug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20) | Kirby Institute | St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | Both | 80 | Phase 4 | Australia |
325. 遺伝性自己炎症疾患
臨床試験数 : 7 / 薬物数 : 16 - (DrugBank : 6) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03304717 (ClinicalTrials.gov) | December 2022 | 4/8/2017 | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Aicardi Goutières Syndrome | Drug: Tenofovir (TDF) and Emtricitabine (FTC);Other: Placebo | Children's Hospital of Philadelphia | National Institutes of Health (NIH);Emerson Resources;Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Human Genome Research Institute (NHGRI);Gilead Sciences | Not yet recruiting | 2 Years | 18 Years | All | 34 | Phase 1/Phase 2 | United States |